Lisata Therapeutics announced the acquisition of clinical-stage biotechnology company Marea Therapeutics alongside an oversubscribed $225 million private placement. The transaction expands Lisata into first-in-class cardioendocrine therapeutics developed through human genetics. Proceeds will primarily fund Marea candidates MAR001/005 and MAR002 through an ongoing Phase 2b trial in severe hypertriglyceridemia and a Phase 2 trial in acromegaly, with topline data anticipated in the fourth quarter of 2027. Marea equity holders received 1.79 million Lisata common shares and 211,365.213 Series C non-voting convertible preferred shares, while private placement investors purchased the preferred stock at approximately $1,491.37 per share, equivalent to $1.4914 per common share on an as-converted basis. Following the transaction, former Marea holders will own about 59.54% of Lisata, private placement investors 38.07%, and existing Lisata holders 2.39% on an as-converted basis. Lisata stockholders must vote at a future meeting on converting the preferred shares into common stock at a 1-to-1,000 ratio. The company also disclosed litigation involving Kuva Labs and a workforce reduction affecting approximately 72% of full-time employees. Lisata shares were up 20.41% at $1.77 at publication.